progressively loses DNA methylation during development. XCI in marsupials has been suggested to be controlled by an RNA called RSX, which is encoded by and coats the inactive X chromosome.

"Instead, this flexible region allows it to move between different nuclear compartments—enabling it to interact with RNA-processing machinery and help shape how gene messages are finalized." ...

AbbVie is entering a collaboration and license option deal with ADARx Pharmaceuticals to develop a new type of RNA technology for disease areas like neuroscience, immunology and oncology.

RNA splicing is a modification of the nascent pre-messenger RNA (pre-mRNA) transcript in which introns are removed and exons are joined prior to translation. For many eukaryotic introns, splicing ...

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...

Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure therapy in mid-stage ...

N6-methyladenosine (m6A) is the most common form of messenger RNA modification in eukaryotes and has been implicated in cardiac development and disease. However, the role of m6A in DiaCM and in the ...